FINHUB Insights

ABBV · Q2 FY26 · Apr 1 – Jun 30, 2026

AbbVie Q2 FY26: where the revenue came from and where it went

AbbVie Q2 FY26: revenue $17.0B (+10% year over year). Net profit $3.6B. Largest cohort Skyrizi $5.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Aug 3, 2026 10-Q
Sankey diagram of AbbVie's income statement for Q2 FY26: revenue of $17.0 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$17.0B +10% year over year
Gross profit$12.7B 75% margin
Operating profit$6.4B 38% margin
Net profit$3.6B 21% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 17.0 100% +10%
Skyrizi 5.5 32% +24%
Neuroscience 3.2 19% +20%
Rinvoq 2.5 15% +25%
Oncology 1.6 10% −3%
Other 1.5 9%
Aesthetics 1.3 8% +0%
Humira 0.8 4% −36%
Other key products 0.6 3% −43%
Cost of revenue−4.325%
Gross profit12.775% margin+3pp
SG&A−3.621%+0pp
Other−2.616%+0pp
Operating profit6.438% margin+6pp
Tax−0.7
Interest & other costs−2.2
Net profit3.621%+15pp
Filing on EDGAR More quarters of ABBV

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters